Table 1 Study Design 1. Budesonide/formoterol reliever therapy vs budesonide/formoterol fixed dose maintenance therapy
From: Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma
Papi et al.12 | Reliever Therapy | Maintenance Therapy | Relative Risk (95% CI) | P |
|---|---|---|---|---|
Risk of severe exacerbations: | ||||
 (No. participants with at least one severe exacerbation/ No. participants randomised to treatment regimen) | 31/424 (7.3%) | 31/442 (7.0%) | 1.04 (0.65 to 1.68) | 0.87 |
| Â | Â | Â | Ratio | Â |
Cumulative dose: | Â | Â | Â | Â |
Budesonide (mg) | 24.5 | 116.8 | 0.21 | Â |
Formoterol (mg) | 0.69 | 3.2 | 0.22 | Â |
Potency: | Â | Â | 4.6 (2.9 to 7.3) | Â |
| Â | Â | Â | Difference (95% CI) | Â |
FEV1 (L, change from baseline, mean (SD)) | −0.16 (0.37) | −0.01 (0.34) | 0.15 (0.09 to 0.20) | < 0.0001 |
ACQ score (mean change from baseline) | 0.25 (0.92) | 0.06 (0.74) | −0.21 (− 0.34 to − 0.08) | < 0.002 |